Victory Capital Management Inc. Makes New Investment in Abcam plc (NASDAQ:ABCM)

Victory Capital Management Inc. bought a new position in shares of Abcam plc (NASDAQ:ABCM – Get Rating) during the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 1,269,247 shares of the company’s stock, valued at approximately $19,749,000. Victory Capital Management Inc. owned 0.55% of Abcam at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. 1832 Asset Management L.P. bought a new position in shares of Abcam in the 1st quarter worth about $32,000. JPMorgan Chase & Co. raised its position in shares of Abcam by 48.7% in the 1st quarter. JPMorgan Chase & Co. now owns 3,044 shares of the company’s stock worth $56,000 after acquiring an additional 997 shares in the last quarter. Van ECK Associates Corp raised its position in shares of Abcam by 41.4% in the 4th quarter. Van ECK Associates Corp now owns 3,536 shares of the company’s stock worth $55,000 after acquiring an additional 1,035 shares in the last quarter. UBS Group AG raised its position in shares of Abcam by 520.3% in the 4th quarter. UBS Group AG now owns 4,249 shares of the company’s stock worth $66,000 after acquiring an additional 3,564 shares in the last quarter. Finally, New York State Common Retirement Fund bought a new position in shares of Abcam in the 4th quarter worth about $121,000. 13.91% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Royal Bank of Canada boosted their target price on Abcam from $21.50 to $23.00 in a research report on Friday, April 28th.

Abcam Stock Down 0.7 %

Shares of Abcam stock opened at $16.81 on Monday. Abcam plc has a one year low of $12.48 and a one year high of $18.38. The business has a 50-day simple moving average of $15.14 and a 200 day simple moving average of $15.40.

Abcam Company Profile

(Get Rating)

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools.